complement 3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis
Rare disease · 2026–2026
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pegcetacoplan Treatment of patients aged 12 years and older with complement 3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis… | Mar 2026 | Not recommended | 1 individuals |
What the PBS pays
$8M in government benefit over 2024–25, across 246 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pegcetacoplan | $8.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.